Fiduciary Alliance LLC Makes New Investment in MiMedx Group, Inc. (NASDAQ:MDXG)

Fiduciary Alliance LLC bought a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) during the 4th quarter, Holdings Channel reports. The fund bought 16,650 shares of the company’s stock, valued at approximately $160,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. purchased a new position in MiMedx Group during the 3rd quarter valued at $30,000. Point72 Asset Management L.P. purchased a new position in shares of MiMedx Group during the second quarter valued at about $40,000. Point72 DIFC Ltd raised its stake in MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock worth $45,000 after buying an additional 4,275 shares in the last quarter. Entropy Technologies LP purchased a new stake in MiMedx Group in the third quarter worth about $64,000. Finally, Orion Capital Management LLC boosted its position in MiMedx Group by 46.3% during the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock valued at $69,000 after acquiring an additional 3,700 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Trading Up 0.6 %

Shares of NASDAQ MDXG opened at $8.61 on Wednesday. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The firm has a 50-day moving average of $9.04 and a 200 day moving average of $7.35. The stock has a market cap of $1.27 billion, a P/E ratio of 15.65 and a beta of 1.96.

Analysts Set New Price Targets

Separately, StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, MiMedx Group has an average rating of “Buy” and an average target price of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.